Sk Life Drug Patent Portfolio
Sk Life owns 1 orange book drug protected by 2 US patents Given below is the list of Sk Life's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11654133 | Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy | 16 Jun, 2039 | Active |
| US7598279 | Neurotherapeutic azole compounds | 30 Oct, 2032 | Active |
Latest Legal Activities on Sk Life's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sk Life.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Electronic Review
Critical
| 07 Jun, 2024 | US7598279 |
| Mail Pub Notice re 312 amendment | 20 Mar, 2024 | US7598279 |
|
Email Notification
Critical
| 20 Mar, 2024 | US7598279 |
| Post Issue Communication - Certificate of Correction Denied | 15 Mar, 2024 | US7598279 |
| POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 14 Mar, 2024 | US7598279 |
|
Patent Term Extension Certificate
Critical
| 09 Nov, 2023 | US7598279 |
| Notice of Final Determination -Eligible | 09 Aug, 2023 | US7598279 |
|
FDA Final Eligibility Letter
Critical
| 13 Jul, 2023 | US7598279 |
| Recordation of Patent eGrant | 23 May, 2023 | US11654133 |
|
Recordation of Patent Grant Mailed
Critical
| 23 May, 2023 | US11654133 |
| Patent eGrant Notification | 23 May, 2023 | US11654133 |
|
Electronic Review
Critical
| 23 May, 2023 | US11654133 |
| Mail Patent eGrant Notification | 23 May, 2023 | US11654133 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 May, 2023 | US11654133 |
|
Email Notification
Critical
| 23 May, 2023 | US11654133 |
Sk Life's Family Patents
Sk Life Drug List
Given below is the complete list of Sk Life's drugs and the patents protecting them.
1. Xcopri
Xcopri is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11654133 | Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy |
16 Jun, 2039
(13 years from now)
| Active |
| US7598279 | Neurotherapeutic azole compounds |
30 Oct, 2032
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xcopri's drug page